BR112022018055A2 - Carbonato de cálcio amorfo para tratamento de acidose. - Google Patents

Carbonato de cálcio amorfo para tratamento de acidose.

Info

Publication number
BR112022018055A2
BR112022018055A2 BR112022018055A BR112022018055A BR112022018055A2 BR 112022018055 A2 BR112022018055 A2 BR 112022018055A2 BR 112022018055 A BR112022018055 A BR 112022018055A BR 112022018055 A BR112022018055 A BR 112022018055A BR 112022018055 A2 BR112022018055 A2 BR 112022018055A2
Authority
BR
Brazil
Prior art keywords
acidosis
treatment
calcium carbonate
amorphous calcium
same
Prior art date
Application number
BR112022018055A
Other languages
English (en)
Inventor
Ben Yossi
Blum Yigal
Natan Yehudit
Original Assignee
Amorphical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorphical Ltd filed Critical Amorphical Ltd
Publication of BR112022018055A2 publication Critical patent/BR112022018055A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

CARBONATO DE CÁLCIO AMORFO PARA TRATAMENTO DE ACIDOSE. A presente invenção é direcionada a partículas ACC estabilizadas por pelo menos um agente estabilizador, uma composição farmacêutica incluindo as mesmas, e métodos de uso da mesma, como para tratar ou prevenir uma doença ou condição relacionada à acidose em um sujeito que precisa dela.
BR112022018055A 2020-03-11 2021-01-28 Carbonato de cálcio amorfo para tratamento de acidose. BR112022018055A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062987952P 2020-03-11 2020-03-11
PCT/IL2021/050103 WO2021181372A1 (en) 2020-03-11 2021-01-28 Amorphous calcium carbonate for treatment of acidosis

Publications (1)

Publication Number Publication Date
BR112022018055A2 true BR112022018055A2 (pt) 2022-10-18

Family

ID=77670497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018055A BR112022018055A2 (pt) 2020-03-11 2021-01-28 Carbonato de cálcio amorfo para tratamento de acidose.

Country Status (9)

Country Link
US (1) US20230124095A1 (pt)
EP (1) EP4117685A4 (pt)
JP (1) JP2023517927A (pt)
CN (1) CN115835871A (pt)
AU (1) AU2021235449A1 (pt)
BR (1) BR112022018055A2 (pt)
CA (1) CA3171001A1 (pt)
IL (1) IL296291A (pt)
WO (1) WO2021181372A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054523A1 (en) * 2022-09-07 2024-03-14 Ph Science Holdings Inc. Methods and compositions for increasing mitochrondrial biogenesis
CN117562869A (zh) * 2023-05-05 2024-02-20 中南大学湘雅医院 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102258500B (zh) * 2009-03-26 2012-11-28 成都康华生物制品有限公司 流感口服缓释疫苗及其制备方法
CA2759795C (en) * 2009-04-30 2016-11-29 Midwestern University Method and composition for treating diabetic ketoacidosis
ES2831699T3 (es) * 2011-12-13 2021-06-09 Amorphical Ltd Un carbonato de calcio morfo para el tratamiento de la mala absorción de calcio y los trastornos metabólicos óseos
JP6860473B2 (ja) * 2014-07-31 2021-04-14 アモーフィカル リミテッド． 非晶質炭酸カルシウムの液体および半固体の非水性製剤
CN107921060A (zh) * 2015-06-04 2018-04-17 艾玛菲克有限公司 用于吸入施用、舌下施用或含服施用的无定形碳酸钙的组合物
ES2952537T3 (es) * 2016-01-18 2023-11-02 Amorphical Ltd Carbonato de calcio amorfo estabilizado para el tratamiento de enfermedades o afecciones neurológicas, musculares y de infertilidad

Also Published As

Publication number Publication date
CN115835871A (zh) 2023-03-21
CA3171001A1 (en) 2021-09-16
IL296291A (en) 2022-11-01
EP4117685A1 (en) 2023-01-18
AU2021235449A1 (en) 2022-10-06
US20230124095A1 (en) 2023-04-20
EP4117685A4 (en) 2024-03-20
JP2023517927A (ja) 2023-04-27
WO2021181372A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
BR112022018055A2 (pt) Carbonato de cálcio amorfo para tratamento de acidose.
BR112018003845A2 (pt) auxiliares cirúrgicos com medicamentos afetados por materiais ativadores
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112018068906A2 (pt) composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
BR112015029144A2 (pt) formulações de gel para guiar radioterapia
BR112022023271A2 (pt) Compostos
BR112023022451A2 (pt) Composto triazina substituído
BR112021020302A2 (pt) Composição, e método de tratamento de um sujeito com câncer
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
BR112018003817A2 (pt) materiais auxiliares cirúrgicos com medicamentos afetados por ativadores
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
BR112018017233A2 (pt) uso de i. butyriciproducens e/ou e. hallii, e, composição
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
BR112022015046A2 (pt) Uso de forsitina e/ou seus derivados, método para a inibição da proteína 3clpro do vírus covid-19, uso de composição de forsitina/forsitosídeo, métodos para uso contra o vírus covid-19 ou para o tratamento de doenças causadas pelo vírus covid-19, composição de forsitina/forsitosídeo e medicamento compreendendo uma composição de forsitina/forsitosídeo
BR112022023928A2 (pt) Uso de canabidiol para o tratamento do transtorno do espectro autista
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
BR112018003843A2 (pt) compostos auxiliares cirúrgicos tendo medicamentos liberados de maneira controlável dos mesmos
BR112014032627A8 (pt) Pró-fármacos de rebamipida, método para produzir o mesmo, e uso do mesmo
BR112021021682A2 (pt) Formulação de implante aquosa injetável que contém ácido ascórbico
BR112016011727A2 (pt) Antagonistas de gastrina para o tratamento e prevenção de osteoporose
BR112022009066A2 (pt) Ezetimiba para uso em tratamento de câncer
BR112014025973A2 (pt) preparação e método para prevenir e tratar a osteoporose e fraturas ósseas